[p4–552]: an Analytical Framework to Project the Potential Medicare Cost Benefit of Intepirdine (rvt101) in Mild‐moderate Alzheimer's Disease
Year: 2017
Type: article
Abstract: The Dependence Scale (DS) captures a combination of the cognitive, functional, and psychiatric changes that occur in Alzheimer's disease (AD) and is strongly correlated with cost of patient care. As reported previously, combination therapy with donepezil and 35 mg intepirdine (RVT101), an oral 5HT6 antagonist in development for the treatment of mild-moderate AD, was projected based on a conversion algorithm to reduce progression in Dependence Level (DL) compared to donepezil monotherapy using data from a placebo-controlled study. Here we examine potential Medicare cost differences associated with this reduced DL progression. The Alzheimer's Disease Cooperative Study – Activities of Daily Living Scale (ADCS-ADL) was measured in a 48-week study of intepirdine vs. placebo, on top of stable donepezil, in subjects with mild to moderate AD (n=684). The ADCS-ADL was converted to DL using a published algorithm. Total costs were estimated from the Predictors 2 study using Medicare costs and assigned to this study. Informal caregiving costs were not included. Cost changes from baseline were compared between treatment groups. Estimated Medicare costs were higher at more severe DLs, ranging from $2,684 for DL=0/1 to $11,218 for DL=4/5. Annual costs associated with the donepezil monotherapy group were projected to increase by an average of $356 over all visits, while annual costs associated with the 35 mg intepirdine plus donepezil combination therapy group were projected to decrease by $42. The magnitude of annual cost benefit associated with intepirdine treatment was projected to range from $289 to $372 based on baseline DL. In this analytical framework, combination therapy with 35 mg intepirdine and donepezil was associated with projected annual cost benefits for Medicare between $289 and $372 compared to donepezil monotherapy. Intepirdine is currently being evaluated in a global Phase 3 study in mild-moderate AD with data expected in 2017.
Source: Alzheimer s & Dementia
Authors: Carolyn W. Zhu, Ebenezer Asare, Shankar Ramaswamy, Ilise Lombardo, Yaakov Stern
Institutions: Icahn School of Medicine at Mount Sinai, Columbia University
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2765735006